Valye reports for unlimited access

lululemon athletica inc. operates as a designer, retailer, and distributor of technical athletic apparel, footwear, and accessories globally. The company organizes its operations into four regional markets: Americas, China Mainland, Asia Pacific (APAC), and Europe and Middle East (EMEA). It sells products through company-operated stores, e-commerce platforms, wholesale accounts, license and supply arrangements, and a re-commerce program. The company had 811 company-operated stores as of February 1, 2026. lululemon's fiscal year ends on the Sunday closest to January 31, typically a 52-week year. The company experiences seasonality common to retail apparel, with significant operating profit in the fourth quarter due to holiday sales and international events such as Lunar New Year and Singles Day. lululemon maintains a strong liquidity position with cash and cash equivalents of $1.8 billion and a current ratio of 2.26 as of February 1, 2026. The company has a $600 million unsecured revolving credit facility maturing in 2030 with no borrowings outstanding. Capital expenditures for 2026 are planned between $725 million and $745 million. The company hedges foreign currency exposure related to its international subsidiaries. lululemon faces risks including brand reputation, competition, supply chain challenges, inflation, and foreign currency fluctuations. The company’s internal controls over financial reporting were assessed as effective as of February 1, 2026.

Fold Holdings, Inc. is a publicly traded company on Nasdaq under the ticker FLD. It is incorporated in Delaware and classified as an emerging growth company. The company has reported significant net losses and negative earnings per share for the fiscal year ended December 31, 2025. Its liquidity ratios as of the same date indicate current liabilities exceed current assets, with a current ratio of 0.86 and a cash ratio of 0.36. Fold Holdings has been actively expanding its Bitcoin treasury and has secured a substantial equity purchase facility to support this strategy. The company is also developing a credit card product, pending third-party service provider agreements. Recent executive appointments and analyst coverage suggest a focus on operational growth and market positioning.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for idiopathic pulmonary fibrosis (IPF)-related chronic cough. Its lead product candidate is nalbuphine extended-release (ER) tablets. The company has engaged with the FDA and received alignment on its clinical development program, including plans for two pivotal Phase 3 trials and supporting Phase 1 studies. The Phase 3 trials are designed as randomized, double-blind, placebo-controlled, multicenter, global studies evaluating the safety and efficacy of nalbuphine ER at 54 mg twice daily dosing. The trials differ in patient enrollment size and duration, with primary efficacy endpoints based on objective cough frequency measurements. As of the fiscal year ended December 31, 2025, Trevi reported a net loss and maintains strong liquidity with substantial cash, short-term investments, and a high current ratio. The company is not involved in any material legal proceedings. Recent analyst coverage has been predominantly positive, with multiple buy and outperform recommendations.

NextNav Inc. delivers complementary PNT solutions that enhance and back up GPS by using a terrestrial network of transmitters operating on low-band spectrum. Its core technologies include Pinnacle, which provides accurate altitude data using barometric sensors, and TerraPoiNT, a terrestrial GPS-like 3D PNT system. The company is evolving its platform to NextGen, which integrates 5G NR positioning reference signals to deliver both PNT and broadband data services on the same spectrum. NextNav holds FCC licenses covering significant low-band spectrum in the U.S. and pursues regulatory approvals to optimize this spectrum for 5G and PNT use. Its services target wireless carriers, application developers, government entities, and device manufacturers, with partnerships including AT&T for Pinnacle deployment and international expansion with MetCom in Japan. The company operates a network operations center and maintains strong data privacy and security practices. Competition includes other complementary PNT technologies such as eLORAN, LEO satellite systems, and Broadcast Positioning System. Financially, NextNav has generated limited revenue and incurred significant net losses, relying on debt and equity financing to fund operations and growth.

IZEA Worldwide, Inc. operates as a publicly traded company headquartered in Orlando, Florida. The company maintains strong liquidity with significant cash reserves and a high current ratio as of the end of 2025. IZEA has reported modest net income and earnings per share of zero for the fiscal year 2025. The company has an active share repurchase program authorized to repurchase up to $8.6 million of common stock. Recent leadership changes include appointments to key executive roles such as CEO and executive vice presidents. IZEA regularly discloses financial results and corporate developments through SEC filings and public earnings calls.

Oklo Inc. develops and plans to deploy next-generation fast fission nuclear power plants called Aurora powerhouses, designed to produce 15 to 75 megawatts of electricity and potentially larger outputs. These powerhouses can operate on fresh, recycled, or down-blended nuclear fuel, leveraging fast neutron technology demonstrated by the Experimental Breeder Reactor-II. Oklo’s business model is to build, own, and operate these powerhouses and sell electricity and heat directly to customers via power purchase agreements, enabling recurring revenue and faster adoption. The company is also commercializing advanced nuclear fuel recycling and fuel fabrication technologies to convert used nuclear fuel into usable fuel, aiming to deploy a commercial-scale recycling facility in the early 2030s. Oklo has secured key regulatory milestones including site permits at the Idaho National Laboratory, a fuel award of HALEU, and positive NRC licensing readiness assessments. The company has a robust pipeline of customer engagements, including large data center operators and utilities, with master power agreements totaling over 18,000 MWe in capacity. Financially, Oklo reported significant operating losses in 2025 but maintains strong liquidity to fund ongoing operations and capital expenditures. The company faces risks from supply chain disruptions, inflation, regulatory delays, and cost uncertainties inherent in first-of-a-kind nuclear facilities.

Farmers National Banc Corp is a regional bank headquartered in Ohio, publicly traded on NASDAQ under the ticker FMNB. The company reported annual revenue of approximately $280 million and net income of $54.6 million for the fiscal year ended December 31, 2025. It has approximately 37.7 million common shares outstanding as of early 2026. The company is in the process of merging with Middlefield Banc Corp, a transaction approved by shareholders and subject to regulatory approvals and customary closing conditions. The merger aims to combine operations and realize strategic benefits, though it carries risks related to integration, retention of key personnel, and transaction costs. The company operates in a regional banking environment influenced by U.S. economic and regulatory conditions.

HealthEquity, Inc. operates as a technology-enabled service provider specializing in the administration of health savings accounts (HSAs) and other consumer-directed benefits (CDBs) such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA, and commuter benefits. The company serves consumers primarily through employer clients, benefits brokers, and a network of over 200 integrated partners including health plans and retirement plan recordkeepers. HealthEquity's proprietary cloud-based platform integrates account administration, payment processing, benefits enrollment, claims processing, investment advisory services, and a healthcare marketplace. The company has established a significant market presence, holding approximately 20% of the HSA market by assets as of mid-2025 and administering nearly 18 million total accounts. Revenue streams include service fees, custodial revenue from HSA cash held by insurance and banking partners, and interchange fees from payment card transactions. HealthEquity invests in technology modernization, including AI, to improve customer service and operational efficiency. The company also pursues growth through selective acquisitions, such as the BenefitWallet HSA portfolio acquired in fiscal 2025.

BlackSky Technology Inc. is a space-based technology company founded in 2014 that delivers real-time imagery, analytics, and high-frequency monitoring of critical global locations and economic assets. The company operates a proprietary constellation of high-resolution, low earth orbit small satellites, including advanced Gen-3 satellites with electro-optical and short-wave infrared imaging capabilities. BlackSky's AI-enabled BlackSky Spectra software platform provides customers with tasking, analytics, and multi-intelligence data fusion, accessible via web and APIs. The company offers subscription-based space-based intelligence and AI services, sovereign Mission Solutions enabling customers to own and operate satellites, and advanced technology programs for R&D and integration. Its customer base is weighted towards U.S. federal government agencies, international governments, and a smaller commercial segment. BlackSky emphasizes a vertically integrated satellite manufacturing process and AI automation to deliver rapid, scalable intelligence at competitive economics.

AN2 Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing novel therapies targeting rare diseases and serious infections. The company is actively engaged in clinical trials, including a recently FDA-cleared trial for Epetraborole targeting Mycobacterium abscessus lung disease. Its financial position as of the end of 2025 shows a net loss consistent with clinical-stage operations and strong liquidity supported by cash reserves and recent capital raises. The company has experienced operational adjustments such as downsizing and trial enrollment pauses, which are common in the biotech development cycle.

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company developing seralutinib, an inhaled small molecule inhibitor targeting PDGFR, CSF1R, and c-KIT pathways, for the treatment of pulmonary hypertension (PH), including pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). The company has completed Phase 2 and Phase 3 clinical trials of seralutinib, with the Phase 3 PROSERA trial enrolling 390 PAH patients and showing a placebo-adjusted improvement in six-minute walk distance (6MWD) at Week 24 of 13.3 meters, narrowly missing the prespecified alpha threshold. Subgroup analyses indicate greater benefit in higher risk patients. Gossamer Bio has a collaboration agreement with Chiesi for global development and commercialization, sharing costs and profits in the U.S. The company is focused on regulatory engagement with the FDA to define the path forward for seralutinib, including NDA readiness. Financially, the company reported a net loss of $170.4 million for 2025, with cash and short-term investments totaling approximately $136.9 million at year-end. The company continues to manage its capital structure and strategic options amid ongoing clinical data analysis and regulatory discussions.

Academy Sports & Outdoors, Inc. is a full-line sporting goods and outdoor recreation retailer in the United States with a mission to provide "Fun for All." Founded in 1938, the company operates 322 stores across 21 contiguous states, primarily in the southern U.S. Its product assortment focuses on four main categories: outdoors, sports & recreation, apparel, and footwear, offered through a mix of leading national brands and 19 private label brands. The company emphasizes a value-based, localized merchandising strategy tailored to a broad customer base including families and casual participants. Stores average about 70,000 gross square feet and are strategically located near major highways and retail centers. The company supports its physical stores with an e-commerce platform and has launched a loyalty program to deepen customer engagement. Academy operates three distribution centers to efficiently serve its store network and e-commerce operations. The business experiences seasonal sales fluctuations tied to holidays and seasonal product demand. Academy competes in a highly competitive retail environment, differentiating itself through its broad assortment, value proposition, and omnichannel capabilities.

Valneva SE is a specialty vaccine company formed in 2013 through the merger of Intercell and Vivalis, listed on Nasdaq and Euronext Paris. It develops, manufactures, and commercializes prophylactic vaccines addressing unmet medical needs. The company markets three proprietary travel vaccines: IXIARO (Japanese encephalitis), DUKORAL (cholera and traveler’s diarrhea), and IXCHIQ (chikungunya). IXCHIQ is approved in Europe, Canada, Brazil, and the UK but faced regulatory suspension and voluntary withdrawal of U.S. applications in 2026. Valneva’s clinical pipeline includes VLA15, a Phase 3 Lyme disease vaccine candidate developed with Pfizer, Shigella4V2 in Phase 2, and VLA1601 for Zika in Phase 1. The company has a sophisticated European manufacturing infrastructure and a commercial presence in multiple countries. Its strategy focuses on advancing late-stage candidates, driving commercial growth, and pursuing collaborations. Financially, Valneva reported €174.7 million revenue and a net loss of €115.2 million in 2025, with liquidity to fund operations for at least 12 months [S1][N3][N6].

AIRWA INC. operates primarily through its subsidiaries, focusing on AI technology and services tailored to specialist industries such as healthcare, industrial manufacturing, and autonomous driving. The company has expanded its operations by acquiring full ownership of its Hong Kong-based subsidiary and a Malaysian AI-specialist company. Its business model involves providing end-to-end AI services structured around interconnected modules that create a closed-loop system for continuous data and model improvement. The company is listed on the Nasdaq Capital Market under the ticker YYAI and maintains strong liquidity as per its latest SEC filings.

Kestra Medical Technologies, Ltd. is a Nasdaq-listed company (ticker KMTS) engaged in medical technology, with recent public disclosures and earnings transcripts providing insight into its operations. The company has shown strong revenue growth in recent quarters and maintains robust liquidity. Kestra Medical has formed strategic partnerships to enhance its diagnostic offerings, notably in cardiac recovery. The company completed a significant public offering in late 2025, bolstering its capital base. Analyst coverage is active, with multiple firms maintaining positive recommendations.

Skkynet Cloud Systems, Inc. is a technology company incorporated in Nevada with principal offices in Canada. The company reported modest quarterly revenue and a net loss in its latest SEC filings. It holds a solid liquidity position with nearly twice as many current assets as current liabilities. The company is involved in an Industrial AI development project supported by Canadian government funding. Public information on its specific products, services, and market positioning is limited.

Maison Solutions Inc. is a Delaware-based company publicly traded on Nasdaq under the ticker MSS. It is classified as a smaller reporting company and thus provides limited risk disclosures. The company reported approximately $29.5 million in revenue and a net loss of $5.2 million for the trailing period ending January 31, 2026. Liquidity metrics show a current ratio below 1, indicating current liabilities exceed current assets. The company has issued senior secured convertible promissory notes with detailed conversion and default provisions. Operationally, the company completed a store renovation in El Monte in late 2024. There is limited public information on the company's sector, industry, or detailed business model.

Pharma-Bio Serv, Inc. is a compliance and technology transfer consulting firm headquartered in Puerto Rico, serving pharmaceutical, chemical, biotechnology, medical device, cosmetics, and food industries primarily in Puerto Rico, the United States, and Europe, with limited presence in Brazil. The company offers a broad range of compliance-related consulting services, employing experienced professionals with advanced degrees in health sciences and engineering. It operates through three reportable segments: Puerto Rico consulting, United States consulting, and Europe consulting, each managed independently. Revenue is mainly generated from time and material contracts and short-term fixed-fee contracts, recognized over time as services are delivered. The company maintains a concentrated customer base with significant revenues from a few major clients. Recent operational adjustments include transitioning headquarters to a virtual environment to enhance competitiveness. The company holds tax grants from Puerto Rico authorities, with one grant recently expired and under renegotiation. Liquidity remains strong with substantial cash, marketable securities, and a high current ratio as of January 31, 2026.

Telomir Pharmaceuticals, Inc. operates as a development-stage pharmaceutical company focused on advancing Telomir-1, a preclinical drug candidate licensed exclusively from MIRALOGX. The company does not own the underlying intellectual property but holds exclusive rights to develop and commercialize Telomir-1 in North America. Telomir-1 is in preclinical development with research indicating potential therapeutic effects in type 2 diabetes and progeria. The company relies on third-party contract research organizations and manufacturers for development and production. Telomir has no revenues and has incurred significant net losses since inception. Its financial position as of late 2025 shows sufficient capital to support operations into early 2027, but additional funding will be necessary to continue development and commercialization efforts. The company faces operational, intellectual property, and financial risks typical of early-stage biopharmaceutical enterprises.

Art Technology Acquisition Corp. is a blank check company incorporated in the Cayman Islands in August 2025. Its business model is to identify and consummate an initial business combination through merger, share exchange, or asset acquisition. The company has no operating revenues and has not commenced operations as of December 31, 2025. It completed its initial public offering in January 2026, raising $253 million, which is held in a trust account invested in U.S. government securities or cash equivalents until a business combination or liquidation. The company intends to focus on targets in technology, art, financial services, and adjacent sectors but may pursue opportunities outside these industries. The management team has significant experience in these sectors and prior blank check company transactions. The company has a single reporting segment and reviews financial performance based on net income or loss and total assets.

ClearPoint Neuro, Inc. develops and commercializes integrated medical device systems used in minimally invasive neurosurgical procedures, primarily targeting brain interventions. The company’s flagship product, the ClearPoint system, integrates hardware, disposable components, and software to facilitate MRI-guided procedures and operating room applications. In 2025, ClearPoint expanded its portfolio by acquiring IRRAS Holdings, adding the IRRA flow Active Fluid Exchange System for neurocritical care, which manages intracranial fluid and pressure in acute care settings. The company also provides consulting and device services to pharmaceutical and biotech partners for drug delivery into the brain, supporting clinical trials and regulatory processes. Manufacturing and assembly are conducted in-house and through third-party suppliers, with quality systems compliant with FDA and international standards. The business model combines device sales, disposables, and service partnerships, with a customer base concentrated among a limited number of hospitals and pharmaceutical companies. The company operates in a competitive landscape with larger established players in neurosurgical devices and neurocritical care.

Harte Hanks Inc is a publicly traded company (ticker: HHS) that provides marketing services and customer care solutions across multiple business segments. The company is engaged in a transformation initiative called Project Elevate, aimed at improving operational efficiency and growth. It operates under an asset-based revolving credit facility extended through 2028, with financial discipline reflected in liquidity ratios as of the end of 2025. Leadership changes include the appointment of David Fisher as President in 2025, overseeing business segments and transformation efforts. The company faces challenges including pension costs and revenue declines reported in recent quarters.

Gaxos.ai Inc. is a technology company focused on reshaping interactions with artificial intelligence across everyday life and high-impact industries. It builds a portfolio of AI-powered solutions designed to be practical and transformative, spanning defense, health and wellness, entertainment, and productivity. The company operates multiple business units: Gaxos Labs develops AI applications including generative AI services for game developers with features like rapid asset creation, monetization tools, and integration with popular game engines. Gaxos Health offers AI-driven personalized health and wellness solutions integrating biometric data. RNK Health markets health-related products through partnerships. Gaxos Gaming develops AI-enabled games and allows users to mint NFTs for unique in-game assets. The company has launched several AI products including UnGPT.ai for enhancing AI-generated text, Art-Gen.AI for AI image and video creation, and Bible Pray AI for spiritual growth. Gaxos.ai also acquired a minority interest in America First Defense.AI LLC in 2026. The company is in an early stage with limited revenue and ongoing losses, supported by capital raises and strong liquidity.

Meshflow Acquisition Corp is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in July 2025. It has no operating business and was formed to effect a merger or similar business combination with one or more companies, primarily targeting the blockchain and digital asset infrastructure sector. The company completed its initial public offering in December 2025, raising $345 million, which is held in a Trust Account invested in short-term U.S. government securities. The company’s management team has significant experience in crypto infrastructure and aims to acquire a company with enterprise value exceeding $1 billion that demonstrates technical and governance maturity. The company has not yet announced any acquisition target and continues to evaluate opportunities. Financially, the company reported net income related to interest income on Trust Account investments and had a strong liquidity position as of December 31, 2025. The company’s business model and financial performance visibility remain limited due to the absence of operating activities.

Capricor Therapeutics, Inc. focuses on developing cell and exosome-based therapies primarily for Duchenne muscular dystrophy (DMD), a rare genetic disorder causing progressive muscle degeneration. Its lead candidate, Deramiocel, is a cell therapy composed of cardiosphere-derived cells designed to address both skeletal and cardiac muscle complications in DMD. The company’s BLA for Deramiocel is under FDA review with a PDUFA target action date in August 2026. Clinical development includes multiple trials, with positive results reported in the Phase 3 HOPE-3 trial demonstrating slowing of disease progression and cardiac benefits. Capricor also pursues exosome-based therapeutics and vaccines, including a SARS-CoV-2 vaccine candidate in early clinical development. Manufacturing capabilities include proprietary processes and facilities to support clinical and potential commercial production. The company has collaborations with Nippon Shinyaku for distribution in the U.S. and Japan and partnerships with government and academic institutions for exosome research. As of the end of 2025, Capricor had no approved products or revenue and reported a net loss, supported by substantial cash reserves.

Oddity Tech Ltd is a foreign private issuer listed on Nasdaq, primarily engaged in the AI-driven cosmetics market. The company sells products through an online direct-to-consumer model and offers a 'Try Before You Buy' program. Revenue recognition follows ASC 606 standards, recognizing revenue upon transfer of control or after trial periods lapse. The company capitalizes software development costs related to its platform. Oddity Tech completed the acquisition of Revela Inc., a U.S. biotechnology company, in 2023. It maintains strong liquidity with significant cash and short-term investments and no outstanding borrowings as of the end of 2025. The company has a comprehensive cybersecurity risk management framework and faces market risks including foreign currency exposure and credit risk. Oddity Tech has announced a $200 million share repurchase program replacing a prior plan. Recent earnings reports indicate revenue and earnings above prior benchmarks but with margin pressures. The company is involved in ongoing securities litigation and maintains effective disclosure and internal controls.

Genius Sports Ltd operates as a B2B provider of technology-led products and services to the global sports, sports wagering, and sports media sectors. The company’s mission is to serve as the operating system of modern sport, connecting sports, betting, and media to fans worldwide. It offers a suite of products including fan engagement experiences, advertising services, performance analysis tools, officiating solutions, and essential technology platforms that generate sustainable revenue streams for sports leagues. Genius maintains extensive relationships with over 400 sports leagues and federations, more than 550 sportsbook brands, and over 250 marketing customers. The company operates a single reportable segment encompassing Betting Content Technology, Media Technology, and Sports Technology services. In early 2026, Genius announced a definitive agreement to acquire Legend, a digital sports and gaming media network, in a transaction valued up to $1.2 billion, supported by committed financing facilities. The acquisition aims to enhance Genius’s strategic positioning and expand its integrated sports and gaming media capabilities [S1].

Elbit Systems Ltd is a global defense technology company engaged in the design, development, manufacture, and integration of advanced defense systems and products. The company operates through five reportable segments: Aerospace, C4I and Cyber, ISTAR and EW, Land, and ESA. Its customer base primarily consists of governmental entities and prime contractors under government defense and homeland security programs, with significant revenues derived from the Israeli Ministry of Defense and the U.S. government. The company employs a hybrid global procurement and supply chain model, focusing on make-to-order production and leveraging supplier performance management to mitigate risks. Quality assurance is maintained through continuous process improvements, certifications, and customer satisfaction measurement. Marketing and sales activities are conducted globally, with subsidiaries and joint ventures supporting local markets. The company faces competition from major international defense contractors and emerging defense technology firms. Elbit Systems maintains a comprehensive cybersecurity management process with oversight from senior management and the Board. Financially, the company reported $7.94 billion in revenues and $534 million in net income for 2025, with a strong liquidity position and compliance with financial covenants. The company’s backlog includes firm commitments for systems and services, recognized according to ASC 606 revenue recognition standards.

Longeveron Inc. operates in the biotechnology sector focusing on stem cell therapies targeting serious conditions such as Hypoplastic Left Heart Syndrome and Alzheimer's disease. The company is advancing clinical development with a Phase 2b trial for Laromestrocel in HLHS, having completed enrollment and engaged with the FDA for regulatory guidance. Intellectual property includes licensed patents for cardiomyogenic cell technology. Financially, the company reported a net loss and negative earnings per share for fiscal 2025, with liquidity supported by cash and current assets exceeding current liabilities. Recent capital raising through a $30 million private placement and cost reduction initiatives reflect ongoing efforts to sustain operations. Leadership changes and partnership explorations are part of the company's strategic activities.

Kalaris Therapeutics, Inc. is focused on developing treatments for retinal diseases with significant unmet needs, primarily through its lead product candidate TH103. TH103 is a fully humanized recombinant fusion protein designed as a VEGF trap with enhanced binding affinity and extended intraocular retention compared to existing anti-VEGF therapies. The company has completed a Phase 1a single ascending dose trial in nAMD patients showing safety and promising efficacy signals, and is currently conducting a Phase 1b/2 multiple ascending dose trial to determine optimal dosing. The company plans to expand TH103 development into other VEGF-mediated retinal diseases. Kalaris has a management team and board with deep expertise in ophthalmology and retina therapeutics, including involvement in the development of approved anti-VEGF drugs. Financially, the company reported a net loss of $43.4 million for 2025 and held approximately $118 million in cash and short-term investments at year-end, supporting operations into late 2027. The company relies on third-party manufacturing and faces competition from established pharmaceutical companies with approved anti-VEGF products.

Mosaic Company is a Delaware-incorporated entity trading on the NYSE under the ticker MOS. It operates with a comprehensive equity compensation program and maintains a significant shareholder base. The company reported over $12 billion in revenue and positive net income for fiscal 2025, supported by substantial current assets relative to liabilities. Mosaic has recently issued senior notes to support corporate financing needs. Market developments and company-specific news indicate active operational and financial management.

George Risk Industries, Inc. manufactures and sells magnetic reed switches and related security products primarily to distributors and OEM manufacturers. Its product portfolio includes explosion-proof contacts for hazardous locations, programmable sensors, glass-break detectors, panic switches, and wireless monitoring devices under development. The company’s operations are closely linked to the housing market, with sales fluctuating accordingly. Management focuses on customer service, product customization, and continuous product innovation. The company is exploring automation and production floor reconfiguration to enhance efficiency and is open to acquisitions to complement its existing operations. Financially, the company reported net sales of $5.659 million for the quarter ended January 31, 2026, a 15.21% increase year-over-year, and net income of $2.48 million for the same period, reflecting strong profitability and operational performance. Liquidity remains robust with a current ratio of 14.42 [S1][S2].

Wewards, Inc. develops and owns a web-based platform that enables consumers to earn Bitcoin rebates by purchasing goods and completing merchant-defined challenges. The company also owns intellectual property for Megopoly, an MMO board game where players earn in-game currency exchangeable for Bitcoin. Wewards intends to generate revenue by licensing its platform and game IP to third parties but has not yet realized revenue from these activities. The company has reduced operating expenses by terminating its office lease and relies on related party financing to fund operations. As of early 2026, Wewards has no revenue, reports net losses, and maintains low liquidity with significant current liabilities.

Nobility Homes Inc is a Florida-based vertically integrated manufacturer and retailer of affordable manufactured and modular homes, operating multiple retail sales centers and an insurance agency subsidiary. The company has over 58 years of experience in the Florida market and focuses on quality and affordability. It sells homes through company-owned retail centers and independent dealers, with a product mix that includes new and pre-owned homes. The company also earns insurance agent commissions from new and renewal policies. Nobility Homes maintains a strong balance sheet with no debt and significant liquidity, supporting its operations and growth in a competitive and inflationary environment [S2].

Idaho Copper Corp operates as a mineral exploration and development company focused on the CuMo Project located in Boise County, Idaho. The project covers approximately 2,640 acres and includes federal unpatented and patented mining claims. The CuMo deposit is part of the Idaho-Montana Porphyry Belt and contains copper, molybdenum, silver, tungsten, and rhenium mineralization. The company completed a Preliminary Economic Assessment in 2020 and is updating it with engineering consultants. It is exploring ore sorting technologies to improve ore grade and processing efficiency. The company completed a reverse stock split in late 2025 to support uplisting efforts. The US Forest Service approved the company's drilling plan with a Finding of No Significant Impact. Idaho Copper plans further exploration and metallurgical studies to advance the project toward feasibility studies. The company has limited financial resources and reported net losses, with liquidity constraints noted in recent SEC filings. It competes with larger mining companies for financing and talent and faces risks related to permitting, commodity prices, and internal controls.

Rise Gold Corp. is a U.S.-based exploration stage mining company focused on the Idaho-Maryland Mine Property in California, owned through its wholly owned subsidiary. The company’s common stock trades on Canadian and U.S. markets. It has no history of commercial production and has incurred losses since inception. The company’s business model centers on exploration, feasibility studies, permitting, and development of its mining property to establish commercially exploitable mineral reserves. It faces significant capital requirements and operational risks typical of early-stage mining companies. The company is actively involved in legal proceedings to assert its constitutional right to mine at its property without a use permit, which is a key aspect of its business strategy. Recent asset sales have been used to repay debt and fund ongoing litigation.